Previous 10 | Next 10 |
2023-06-01 07:07:56 ET Can-Fite Biopharma press release ( NYSE: CANF ): Q1 GAAP EPS of $0.00. Revenue of $0.2M (flat Y/Y). For further details see: Can-Fite Biopharma GAAP EPS of $0.00, revenue of $0.2M
Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, today announced financial results for the three months ended March 31, 2023. Clinical and C...
2023-05-30 10:16:36 ET Can-Fite BioPharma ( NYSE: CANF ) announced the publication of a study titled "Effects of Namodenoson on Pancreatic Carcinoma: Preclinical Evidence" in the Journal of Clinical Oncology supplement of the 2023 ASCO Annual Meeting Proceedings. The pre-clini...
Abstract published online in the Journal of Clinical Oncology supplement of the 2023 ASCO Annual Meeting Proceedings Can-Fite to initiate Phase 2a pancreatic cancer study Namodenoson significantly inhibits growth of pancreatic carcinoma as a stand-alone treatment and in co...
Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer, and liver diseases, today announced its VP of Business Development, Dr. Sari Fishman, will participate in BioEquity Eur...
Exploratory, small, open-label study aims to assess potential efficacy of Namodenoson following strong preclinical results in pancreatic cancer Namodenoson, now in a pivotal Phase 3 liver cancer study, has completely cleared liver cancer in a patient who remains cancer-free 6 years af...
2023-05-02 12:39:37 ET Can-Fite BioPharma ( NYSE: CANF ) stock rose ~6% on Tuesday after the company said it discovered the mechanism of action (MOA) involved with the anti-cancer effect of Namodenoson in pancreatic cancer. The company noted that Namodenoson de-regulates t...
The anti-cancer effect in pancreatic carcinoma is mediated via a key signal transduction pathway According to the American Society of Clinical Oncology (ASCO) in 2020 an estimated 496,000 people were diagnosed with pancreatic cancer globally Can-Fite BioPharma Ltd. (...
2023-04-24 07:30:47 ET Can-Fite BioPharma ( NYSE: CANF ) has announced executive changes to support the Company’s continued success in advancing its pipeline toward commercialization through two pivotal Phase III trials in psoriasis and liver cancer. Motti Farbstein ...
Dr. Pnina Fishman appointed Executive Chairman of the Board Motti Farbstein appointed Chief Executive Officer in addition to continuing as Chief Financial Officer Can-Fite BioPharma Ltd . (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipelin...
News, Short Squeeze, Breakout and More Instantly...
Can-Fite Biopharma Ltd Sponsored ADR Company Name:
CANF Stock Symbol:
NYSE Market:
Can-Fite Biopharma Ltd Sponsored ADR Website:
RAMAT GAN, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, invites investors to a webinar on August 8...
PETACH TIKVA, Israel, July 11, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that it has submitted ...
Liver cirrhosis treatment global market is estimated to reach $29.2 billion by 2030 Ramat Gan, Israel, July 01, 2024 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CFBI), a biotechnology company with a pipeline of proprietary small molecule drugs that addr...